ERBB2 and neoplasm: In univariate analysis, pCR was significantly correlated with tumor subtypes (7.6%, 20.7%, 42.4%, 62.7% and 43.5% for Luminal A, Luminal B HER2−, Luminal B HER2+, HER2+ and triple-negative tumors, respectively; p<0.0001) (Figure 2), cN stage (39.4% and 29.7% for cN0 and cN1, respectively; p<0.0001) and periods (33.6%, 29.6%, 37.6% for P1, P2 and P3, respectively; p=0.011) (Table 5).